Auditory safety evaluations are recommended for any drug administered into the middle ear or that may come in contact with the middle or inner ear tissues. In addition to otically administered compounds, some classes of systemically administered drugs should also be considered for evaluation. […]
MPI Research scientists, Scott Boley, PhD, DABT, Senior Director of General Toxicology and Infusion Toxicology, and Thomas Vihtelic, DVM, PhD, Director of Experimental Therapeutics, with a team of esteemed industry and regulatory drug development experts, will present at the upcoming seminar, Drug Development Boot Camp, November 14-15, 2012 at Harvard University. This […]
MPI Research, the largest single-site preclinical Contract Research Organization (CRO) worldwide, is pleased to announce that its Quantitative Whole-Body Autoradiography (QWBA) laboratory has achieved full GLP validation. Ms. Andrea Knapp, MPI Research scientist, manages the QWBA laboratory. Mr. Brian Knapp, associate Study Director, provides appropriate QWBA study design and interpretation. Together, they have nearly 25 […]
MPI Research is pleased to support the American Association of Pharmaceutical Scientists Annual Meeting and Exposition (AAPS), taking place October 14 – 18, 2012, at McCormick Place, in Chicago, Illinois. We will be delivering multiple scientific presentations at this year’s meeting.
Karina Kwok, PhD, will moderate the “Hot Topics” session, Drug Development at a Small Company, […]
How Can Molecular Imaging Improve My Drug Development Program?
The incorporation of molecular imaging solutions into drug development programs allows investigators to receive rapid results, assess their compound of interest and make critical go/no-go decisions earlier in the development process. At MPI Research, we routinely use cutting-edge technology in molecular imaging and radiochemistry to assist our […]
This issue of Directions in Discovery and Development covers topics in the Discovery arena, with a focus on ocular disease, metabolic disease, drug metabolism, and pharmacokinetics (DMPK). Our Experimental Therapeutics program provides Sponsors with a collaborative approach to evaluating efficacy, proof-of-concept, and translational sciences in many therapeutic areas and covers a wide range of indications. […]
MPI Research will be sharing our scientific highlights at two upcoming European meetings, both being held June 17-20, 2012. […]
Here’s a shocking fact: 346 million people worldwide have diabetes. More than 90 percent of them – including an increasing number of children—have type 2 diabetes, putting them at greater risk for heart disease, stroke, blindness, neuropathy, kidney failure, and death.1 The rising obesity rate – […]
Many baby boomers are entering their twilight years at risk of losing their sight because of age-related eye diseases.
Among the most debilitating is age-related macular degeneration (AMD), the leading cause of blindness among people over the age of 55 in developed nations. In the United States alone, 13 million people are at some stage of the disease.1 The “dry” […]